We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LPLA:NASDAQLPL Financial Holdings Inc. Analysis

Data as of 2026-05-21 - not real-time

$283.83

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

LPL Financial is trading at $283.83, well below its 20‑day SMA of $311.25 and 50‑day SMA of $306.99, indicating a potential short‑term rebound zone near the identified support of $282.78. The RSI of 35 suggests the stock is oversold, while the MACD remains bearish with the line under the signal, signaling mixed momentum. Volatility is elevated at 38.7% over the past 30 days and beta hovers around 1.0, reflecting market‑wide risk exposure. Fundamentally, the company posted a 35% revenue surge to $17.84 bn and beat consensus earnings, with non‑GAAP EPS of $5.60 surpassing estimates. Forward earnings are projected at $28.40 per share, compressing the forward P/E to roughly 10× versus a trailing P/E of 25.6, and analysts forecast a median price target of $403.5, implying ~47% upside. Recent material news highlights a Q1 earnings beat, a $125 million share buyback, and two Stevie® Awards, underscoring operational strength and shareholder return initiatives.
The dividend remains modest at 0.42% with a low payout ratio of 11%, supporting sustainability despite negative operating cash flow. Compared with the industry average P/E of 16.66, LPLA appears overvalued on a traditional basis, yet its strong growth profile and attractive forward valuation tilt it toward a growth‑oriented case. The consensus analyst rating is a “Buy” with 14 contributors, reinforcing confidence in the upside narrative. While regulatory and sector risks are medium, the firm’s U.S. focus keeps geographic and currency risks low. Liquidity is solid, with rising volume and a $22.7 bn market cap, mitigating immediate trading concerns. Overall, the blend of technical support, earnings momentum, and strategic initiatives suggests a cautiously optimistic outlook.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support at $282.78
  • Oversold RSI indicating potential bounce
  • Bearish MACD suggesting limited upside

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • 35% YoY revenue growth and earnings beat
  • Forward P/E ~10× offering valuation upside
  • Analyst median target price implying ~47% upside

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Scalable advisory platform with strong market position
  • Sustainable dividend with low payout ratio
  • Strategic share buyback and award recognitions supporting shareholder value

Key Metrics & Analysis

Financial Health

Revenue Growth35.00%
Profit Margin5.05%
P/E Ratio25.6
ROE20.45%
ROA5.49%
Debt/Equity132.28
P/B Ratio4.0
Op. Cash Flow$-460814016
Industry P/E16.7

Technical Analysis

TrendNeutral
RSI35.0
Support$282.78
Resistance$339.99
MA 20$311.25
MA 50$306.99
MA 200$340.54
MACDBearish
VolumeIncreasing
Fear & Greed Index90.29

Valuation

Target Price$417.21
Upside/Downside46.99%
GradeOvervalued
TypeGrowth
Dividend Yield0.42%

Risk Assessment

Beta1.03
Volatility38.73%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.